Vyome (NASDAQ:HIND) Issues Earnings Results

Vyome (NASDAQ:HIND) issued its quarterly earnings data on Tuesday. The company reported ($0.15) earnings per share (EPS) for the quarter, Zacks reports. Vyome had a negative return on equity of 279.99% and a negative net margin of 270.58%.

Vyome Stock Up 0.5%

Shares of Vyome stock traded up $0.01 during midday trading on Tuesday, hitting $1.98. The company’s stock had a trading volume of 241,894 shares, compared to its average volume of 600,012. The firm has a market capitalization of $13.90 million, a P/E ratio of -0.02 and a beta of 1.38. The stock has a 50-day simple moving average of $2.32 and a 200-day simple moving average of $3.40. Vyome has a 1-year low of $1.75 and a 1-year high of $33.16.

Institutional Trading of Vyome

An institutional investor recently bought a new position in Vyome stock. Millennium Management LLC bought a new position in Vyome Holdings, Inc. (NASDAQ:HIND) in the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm bought 45,144 shares of the company’s stock, valued at approximately $155,000. Millennium Management LLC owned 0.80% of Vyome as of its most recent SEC filing. Hedge funds and other institutional investors own 22.06% of the company’s stock.

Analysts Set New Price Targets

HIND has been the subject of a number of research reports. Weiss Ratings raised Vyome from a “sell (e)” rating to a “sell (e+)” rating in a research note on Friday, May 1st. Litchfield Hills Research initiated coverage on Vyome in a research note on Monday, May 4th. They set a “buy” rating for the company. Finally, Zacks Research raised Vyome to a “hold” rating in a research note on Wednesday, May 6th. Three investment analysts have rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the company. According to MarketBeat.com, the stock presently has an average rating of “Hold” and an average price target of $15.00.

About Vyome

ReShape Lifesciences Inc, a medical device company, provides products and services that manages and treat obesity and metabolic diseases in the United States, Australia, Europe, and internationally. The company’s product portfolio includes Lap-Band System, a minimally invasive long-term treatment of severe obesity and more invasive surgical stapling procedures, such as the gastric bypass or sleeve gastrectomy; and ReShape Vest system, an investigational, minimally invasive, laparoscopically implanted medical device that wraps around the stomach to enable weight loss in obese and morbidly obese patients without cutting or permanently removing portions of the stomach, or bypassing any portion of the gastrointestinal tract.